HomeCompareRSPI vs CHD

RSPI vs CHD: Dividend Comparison 2026

RSPI yields 111111.11% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSPI wins by $1.3838190899465547e+27M in total portfolio value
10 years
RSPI
RSPI
● Live price
111111.11%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.3838190899465547e+27M
Annual income
$1,381,373,456,343,941,000,000,000,000,000,000.00
Full RSPI calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — RSPI vs CHD

📍 RSPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSPICHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSPI + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSPI pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSPI
Annual income on $10K today (after 15% tax)
$9,444,444.44/yr
After 10yr DRIP, annual income (after tax)
$1,174,167,437,892,349,800,000,000,000,000,000.00/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, RSPI beats the other by $1,174,167,437,892,349,800,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSPI + CHD for your $10,000?

RSPI: 50%CHD: 50%
100% CHD50/50100% RSPI
Portfolio after 10yr
$6.919095449732774e+26M
Annual income
$690,686,728,171,970,500,000,000,000,000,000.00/yr
Blended yield
99.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

RSPI
No analyst data
Altman Z
-2461.3
Piotroski
2/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSPI buys
0
CHD buys
0
No recent congressional trades found for RSPI or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSPICHD
Forward yield111111.11%1.28%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$1.3838190899465547e+27M$26.4K
Annual income after 10y$1,381,373,456,343,941,000,000,000,000,000,000.00$1,302.64
Total dividends collected$1.383658847866035e+27M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RSPI vs CHD ($10,000, DRIP)

YearRSPI PortfolioRSPI Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,121,811$11,111,111.11$10,857$157.30+$11.11MRSPI
2$11,561,029,218$11,549,128,879.66$11,814$196.49+$11561.02MRSPI
3$11,232,204,364,934$11,219,834,063,671.13$12,887$245.97+$11232204.35MRSPI
4$10,199,601,320,781,262$10,187,582,862,110,782.00$14,097$308.68+$10199601320.77MRSPI
5$8,656,721,364,988,387,000$8,645,807,791,575,153,000.00$15,473$388.49+$8656721364988.37MRSPI
6$6,867,176,795,058,000,000,000$6,857,914,103,197,462,000,000.00$17,046$490.55+$6867176795058000.00MRSPI
7$5,091,669,942,459,710,000,000,000$5,084,322,063,288,997,000,000,000.00$18,861$621.76+$5091669942459709440.00MRSPI
8$3,528,599,356,203,225,300,000,000,000$3,523,151,269,364,793,600,000,000,000.00$20,973$791.47+$3.5285993562032256e+21MRSPI
9$2,285,638,880,947,370,600,000,000,000,000$2,281,863,279,636,233,000,000,000,000,000.00$23,454$1,012.51+$2.2856388809473705e+24MRSPI
10$1,383,819,089,946,554,900,000,000,000,000,000$1,381,373,456,343,941,000,000,000,000,000,000.00$26,398$1,302.64+$1.3838190899465547e+27MRSPI

RSPI vs CHD: Complete Analysis 2026

RSPIStock

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Full RSPI Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this RSPI vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSPI vs SCHDRSPI vs JEPIRSPI vs ORSPI vs KORSPI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.